文献速递血栓与止血

一种HPA-1a阳性血小板清除剂用于预防胎儿和新生儿同种免疫性血小板减少症:一项随机、单盲、安慰剂对照、单中心、1/2期概念验证研究

An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study.
PubMed 文献 · J Thromb Haemost · 2022-12-22

本研究在HPA-1a阴性健康男性中开展随机单盲安慰剂对照单中心1/2期概念验证研究,评估单剂抗HPA-1a抗体RLYB211(1000 IU)对比安慰剂能否加速清除输注的HPA-1ab血小板。12例受试者随机接受RLYB211(n=9)或安慰剂(n=3),RLYB211在所有受试者中均显著加速血小板清除,队列1B在给药7天后仍可见此效应;2例治疗中出现的不良事件可能与治疗相关,均发生在RLYB211组;12周和24周时无受试者产生HPA-1a抗体。

要点

  • RLYB211在所有受试者中较安慰剂显著加速HPA-1ab血小板清除。
  • 队列1B中该效应在RLYB211给药7天后仍可观察到。
  • 2例治疗中出现的不良事件可能与治疗相关,均发生于RLYB211组。

核心结论

  • 这些数据支持抗HPA-1a抗体可作为有FNAIT受累妊娠风险女性的预防措施的假说。

研究设计与样本

  • 随机、单盲、安慰剂对照、单中心、1/2期概念验证研究(EudraCT:2019-003459-12),纳入HPA-1a和HLA-A2阴性健康男性。
  • 队列1在输注HPA-1ab血小板1小时后静脉给予RLYB211或安慰剂;队列1B先给予RLYB211或安慰剂,1周后输注血小板。
  • 主要终点为给予RLYB211或安慰剂后循环中输注血小板的半衰期,用流式细胞术测定;概念验证定义为相对安慰剂半衰期减少≥90%。
  • 12例受试者分配至队列1或1B,随机接受RLYB211(n=9)或安慰剂(n=3)。

主要发现

  • RLYB211在所有受试者中较安慰剂显著加速HPA-1ab血小板的清除。
  • 队列1B中,该效应在RLYB211给药7天后观察到。
  • 2例治疗中出现的不良事件可能与治疗相关,均发生在RLYB211治疗受试者中。
  • 12周或24周时无受试者产生HPA-1a抗体。

关键数值与推荐

  • 单次抗HPA-1a剂量为1000 IU。
  • 概念验证标准为相对安慰剂半衰期减少≥90%。

临床怎么用

  • 原文结论为这些数据支持抗HPA-1a抗体可作为有FNAIT受累妊娠风险女性的预防措施的假说。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening bleeding disorder of the fetus/newborn. Antibodies against human platelet antigen 1a (HPA-1a) are associated with the most frequent FNAIT cases. There are no approved therapies for FNAIT prevention or treatment. RLYB211 is a polyclonal HPA-1a hyperimmune IgG being developed to prevent FNAIT. OBJECTIVES: To investigate whether a single dose of anti-HPA-1a (1000 IU) could markedly accelerate the elimination of HPA-1ab platelets transfused into healthy, HPA-1a-negative participants as compared with placebo. METHODS: This randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study (EudraCT: 2019-003459-12) included HPA-1a- and HLA-A2-negative healthy men. Cohort 1 received intravenous RLYB211 or placebo 1 hour after transfusion of HPA-1ab platelets. Cohort 1B received RLYB211 or placebo, followed by platelet transfusion 1 week later. Primary endpoint was the half-life of transfused platelets in circulation after administration of RLYB211 or placebo, determined by flow cytometry. Proof of concept was ≥90% reduction of half-life relative to placebo. RESULTS: Twelve participants were allocated to cohort 1 or 1B and randomized to receive RLYB211 (n = 9) or placebo (n = 3). RLYB211 markedly accelerated the elimination of HPA-1ab platelets in all participants vs placebo. In cohort 1B, this effect was observed 7 days after RLYB211 administration. Two treatment-emergent adverse events were possibly related to treatment, both in RLYB211-treated participants. No participants developed HPA-1a antibodies at 12 or 24 weeks. CONCLUSION: These data support the hypothesis that anti-HPA-1a could be used as prophylaxis in women at risk of having an FNAIT-affected pregnancy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Geisen C, Kjaer M, Fleck E, et al. An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study. J Thromb Haemost. 2022. PMID: 36696185. doi:10.1016/j.jtha.2022.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。